A Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis.
Phase 2
- Conditions
- lcerative colitis
- Registration Number
- JPRN-jRCT2080220693
- Lead Sponsor
- AbbVie GK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 255
Inclusion Criteria
Moderately to severely active UC.
Exclusion Criteria
Crohn's disease
History of TB
Pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mayo score at Week 8 and Week 52
- Secondary Outcome Measures
Name Time Method Mayo score at Week 32<br>IBDQ<br>Adverse events